Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15380656 | 0.94 | KDM4E (0.43) | KDM4ETSHRAPLNRLMNAMEN1 | |
| SCHEMBL15380271 | 0.87 | APLNR (0.46) | KDM4ETSHRAPLNRLMNAMEN1 | |
| SCHEMBL28019721 | 0.79 | APLNR (0.43) | KDM4ETSHRAPLNRLMNAMEN1 | |
| SCHEMBL15379753 | 0.76 | APLNR (0.48) | KDM4ETSHRAPLNRLMNAMEN1 | |
| SCHEMBL15380279 | 0.76 | ALDH1A1 (0.51) | KDM4ETSHRLMNAMEN1KMT2A | |
| SCHEMBL15380069 | 0.75 | APLNR (0.47) | KDM4ETSHRAPLNRLMNAMEN1 | |
| SCHEMBL15380404 | 0.74 | ALDH1A1 (0.52) | KDM4ETSHRAPLNRLMNAMEN1 | |
| SCHEMBL15379559 | 0.74 | KMT2A (0.51) | KDM4ETSHRLMNAMEN1KMT2A | |
| SCHEMBL19414333 | 0.73 | APLNR (0.47) | KDM4ETSHRAPLNRLMNAMEN1 | |
| SCHEMBL17470155 | 0.72 | KDM4E (0.46) | KDM4ETSHRAPLNRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107674071-B | Carbazole-containing sulfonamides as cryptochrome modulators | 同步制药公司 | 2021-12-31 | — | — | CN | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| CN-107674071-A | The sulfonamides containing carbazole as cryptochrome conditioning agent | 复位治疗公司 | 2018-02-09 | — | — | CN | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| CN-104640856-B | Carbazole-containing sulfonamides as cryptochrome modulators | 复位治疗公司 | 2017-09-15 | — | — | CN | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| CN-104640856-A | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS INC | 2015-05-20 | — | — | CN | disclosed |
| EP-2855458-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Reset Therapeutics, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| WO-2013170186-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | CRY1, CRY2, CRYAB | KDM4E 3796/4885TSHR 515/4885APLNR 4184/4885 |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | KDM4E 3945/4885TSHR 477/4885APLNR 4108/4885 |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | CRY1, CRY2, CRYAB | KDM4E 3945/4885TSHR 477/4885APLNR 4108/4885 |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | KDM4E 3945/4885TSHR 477/4885APLNR 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.